bluebird bioの空売り状況は、投資家がbluebird bioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

bluebird bio (NASDAQ:BLUE) 株価情報, 空売り情報

bluebird bio

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.

bluebird bio Inc

BLUE HOLDINGS INC by Blue Holdings, Inc.

BLUE WORLD ACQUISITION CORP USD RTS

BLUEPRINT TECHS INC by Blueprint Technologies, Inc.

BLUERIVER ACQUISITION CORP CL A ORD SHS

BLUESCAPE OPPORTUNITIES ACQUISITION CORP CL A

Blue Apron Holdings Inc COM PAR $

Blue Biofuels Inc

Blue Bird Corp

Blue Capital Reinsurance Holdings Ltd

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

BLUE DOLPHIN ENERGY CO by Blue Dolphin Energy Co.

Blue Dolphin Energy Co

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

Blue Energy Ltd

Blue Foundry Bancorp

BLUE GEM ENTERPRISE by Blue Gem Enterprise

Blue Gem Enterprise

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive Entertainment Technology

CANOPUS BIOPHARMA INC by Canopus Biopharma, Inc.

Blue Heaven Coffee Inc

BLUE HORIZON GLOBAL CAP by BLUE HORIZON GLOBAL CAP CORP.

Blue Horizon Global Capital Corp

BLUE LAGOON RESOURCES INC by Blue Lagoon Resources Inc.

Blue Lagoon Resources Inc

BLUE LINE PROTECTION GRP by Blue Line Protection Group, Inc.

Blue Line Protection Group Inc

BLUE MOON GRP UNSP/ADR by Blue Moon Group Holdings Limited

Blue Moon Group Holdings Ltd

Blue Moon Metals Inc

BLUE MOON METALS INC by BLUE MOON METALS INC.

BLUE NOTE MINING INC NEW by Blue Note Mining Inc.

Blue Note Mining Inc

Blue Ocean Acquisition Corp Warrants (02/12/2026)

Blue Ocean Acquisition Corp

Blue Ocean Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Blue Ocean Acquisition Corp Ordinary Shares - Class A

Blue Owl Capital Corporation Common Stock

Blue Owl Capital Corp

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Capital Inc

Blue Ribbon Income Fund

Blue Ridge Bankshares Inc

BLUE RIDGE REAL ESTATE CO by Blue Ridge Real Estate Co.

Blue Ridge Real Estate Co

BLUE RIVER RES LTD ORD by Blue River Resources, Ltd.

Blue River Resources Ltd

BLUE SKY URANIUM CORP by Blue Sky Uranium Corp.

Blue Sky Uranium Corp

Blue Sphere Corp

BLUE STAR FOODS CORP by BLUE STAR FOODS CORP.

Blue Star Foods Corp

BLUE STAR GLOBAL INC by Blue Star Global, Inc.

Blue Star Global Inc

BLUE STAR GOLD CORP by Blue Star Gold Corp.

Blue Star Gold Corp

BLUE STAR HELIUM LTD by Blue Star Helium Ltd.

Blue Star Helium Ltd

BLUE STAR OPPTYS CORP by Blue Star Opportunities Corp.

Blue Star Opportunities Corp

BLUE WATER GLOBAL GRP INC by Blue Water Global Group, Inc.

Blue Water Global Group Inc

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

Blue World Acquisition Corp Warrants (10/01/2029)

Blue World Acquisition Corp

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

BLUEFIRE EQUIPMENT CORP by BlueFire Equipment Corp.

BlueFire Equipment Corp

BLUEHARBOR BANK (NC) by BlueHarbor Bank (Mooresville NC)

BlueHarbor Bank

BlueLinx Holdings Inc

BlueRiver Acquisition Corp Units (1 Ord Share Class A & 1/3 War)

BlueRiver Acquisition Corp

BLUERIVER ACQ CORP A by BlueRiver Acquisition Corp.

BlueRiver Acquisition Corp Warrants (04/01/2026)

BlueRush Inc

BLUESCOPE STEEL LTD by Bluescope Steel, Ltd.

BlueScope Steel Ltd

BLUESCOPE STL UNS/ADR NEW by Bluescope Steel, Ltd.

BLUEBERRIES MEDICAL CO by Blueberries Medical Co.

Blueberries Medical Corp

Bluegreen Vacations Holding Corp Class B

Bluegreen Vacations Holdings Corp Com Cl A

Bluejay Diagnostics Inc

Blueone Card Inc

Blueprint Chesapeake Multi-Asset Trend ETF

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

Bluerock Homes Trust, Inc. Class A Common Stock

Bluerock Homes Trust Inc

BLUESKY DIGITAL ASSET CRP by Bluesky Digital Assets Corp.

Bluesky Digital Assets Corp

BLUESTEM GROUP INC by Bluestem Group Inc.

Bluestem Group Inc

Bluestone Resources Inc

Stockholders that have previously tendered their shares must re-tender their shares
Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR
As previously announced on May 14, 2025, Carlyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird"), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instructions for stockholders to tender their shares into the offer.
Updated Instructions for Stockholders:
<ul>
<li>Contrary to prior instructions, stockholders that have previously tendered their shares must re-tender their shares and complete and sign the letter of election and transmittal attached to the Offer to Purchase. Detailed instructions are available in the Offer to Purchase.</li>
<li>Previously tendered shares will not be valid unless they are re-tendered with an election. If stockholders that previously tendered do not take action, it will have the same effect as withdrawing previously tendered shares from the offer.</li>
<li>Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now.</li>
<li>Stockholders who need assistance with tendering their shares of bluebird may contact the Information Agent, Innisfree M&amp;A Incorporated, by calling toll-free at (877) 825-8793.</li>
</ul>
Details on Amended Agreement:
Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right ("CVR") of $6.84 per share in cash payable upon achievement of a net sales milestone or (y) $5.00 per share in cash. The amended offer price provides an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR. Any shares tendered for which no election is made will receive the original consideration of $3.00 per share in cash plus a CVR per share.
The bluebird board of directors unanimously approved the amended agreement and recommends that all stockholders immediately tender their shares in support of the transaction. The bluebird board of directors continues to believe that the transaction with Carlyle and SK Capital, as amended, represents the only viable option for stockholders to receive consideration for their shares. Absent a majority of stockholders tendering, bluebird is at significant risk of defaulting on its loan agreements with Hercules Capital, and it is extremely unlikely that stockholders would receive any consideration for their shares in a bankruptcy or liquidation.
As previously announced on May 5, 2025, Carlyle and SK Capital have received all required regulatory approvals to complete the transaction, and all parties expect the transaction to be consummated promptly following the successful completion of the ongoing tender offer, which expires one minute after 11:59 p.m. New York City time on May 29, 2025.

News

BLUE

Carlyle And SK Capital Amend Agreement To Acquire bluebird bio, Update Tender Offer Instructions For Stockholders

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement.
Under the terms of the amended agreement, Bluebird stockholders can elect to receive either the original offer of $3.00 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45404624/carlyle-sk-capital-partners-and-bluebird-bio-amend-merger-agreement" rel="noreferrer noopener">$5.00 per share in cash</a>.
The amended offer price provides an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential <a target="_blank" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal" rel="noreferrer noopener">upside of the CVR</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44651650/deal-dispatch-us-ma-is-quiet-but-abroad-volume-is-spiking" rel="noreferrer noopener">Deal Dispatch: US M&amp;A Is Quiet, But Abroad? Volume Is Spiking</a>
Any shares tendered for which no election is made will receive the original consideration of $3.00 per share in cash and a contingent value right per share.
In May, Carlyle and SK Capital received all required regulatory approvals to complete the transaction, and all parties expect the transaction to be consummated promptly following the successful completion of the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45206000/carlyle-and-sk-capital-receive-all-required-regulatory-approvals-to-complete-the-acquisition-of-bl" rel="noreferrer noopener">ongoing tender offer</a>.
In March, Bluebird received an unsolicited, non-binding written proposal from Ayrmid Ltd. Ayrmid proposed to acquire Bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achieving a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps" rel="noreferrer noopener">net sales milestone</a>.
In April, the company said that after three weeks of engagement, including a timeline extension, Ayrmid did not submit a binding proposal to acquire Bluebird and had not obtained the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44835630/bluebird-bio-confirms-that-ayrmid-ltd-has-not-delivered-a-binding-offer-or-obtained-necessary-fina" rel="noreferrer noopener">necessary financing</a>.
Price Action: BLUE stock is up 50.3% to $4.98 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45409509/samsungs-1-7-billion-cooling-spree-buys-flaktgroup-to-target-data-center-boom" target="_blank" rel="noreferrer noopener">Samsung&#8217;s $1.7 Billion Cooling Spree &#8211; Buys FläktGroup To Target Data Center Boom</a></li>
</ul>
Image by Gumbariya via Shutterstock

Biotech

Health Care

Movers

General

Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity

<h3>Gainers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 176.9% to $0.36 during Wednesday's regular session. The company's market cap stands at $10.2 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock moved upwards by 49.89% to $4.96. The market value of their outstanding shares is at $48.5 million. </li>
<li>Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) stock increased by 41.68% to $9.54. The company's market cap stands at $424.4 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 36.11% to $2.69. The company's market cap stands at $8.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock rose 32.0% to $5.94. The company's market cap stands at $111.5 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock rose 24.61% to $0.12. The company's market cap stands at $7.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 54.4% to $0.01 during Wednesday's regular session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock decreased by 53.75% to $0.04. The company's market cap stands at $1.0 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock fell 39.83% to $0.22. The market value of their outstanding shares is at $31.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 23.87% to $0.84. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock decreased by 23.56% to $0.25. The market value of their outstanding shares is at $12.1 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) stock fell 22.45% to $33.27. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

AXDX

BDSX

BMGL

GRAL

KLTO

LUCY

LYRA

PLRZ

SEPN

SILO

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Bluebird Bio shares are trading higher after the company announced the amendment of its merger agreement with Carlyle and SK Capital Partners.

Carlyle, SK Capital Partners And bluebird bio Amend Merger Agreement; Stockholders May Elect To Receive Either $3/Share Plus CVR Of $6.84/Share In Cash Payable Upon Achievement Of A Net Sales Milestone Or $5/Share With No CVR

bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately tender their shares into the offer
Parties expect the merger to be completed promptly following the successful completion of the ongoing tender offer
bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird" or "the Company"), Carlyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received.
No further regulatory approvals are required to complete the transaction. The parties expect to complete the merger promptly following the successful completion of the ongoing tender offer, which is scheduled to expire one minute after 11:59 p.m. New York City time on May 12, 2025, unless the tender offer is further extended or earlier terminated.
Under the terms of the merger agreement, stockholders will receive an upfront payment of $3.00 per share in cash and a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone, for a total potential value of $9.84 per share. The bluebird board of directors (the "Board") unanimously recommends that stockholders tender into the offer.

bluebird bio, Carlyle, SK Capital And Beacon Parent Holdings Receive All Required Regulatory Approvals To Complete bluebird Acquisition

Carlyle Group and Bluebird Bio shares are trading lower. The company, along with SK Capital Partners, announced that the Beacon merger subsidiary has extended the expiration date to acquire the outstanding shares of Bluebird Bio.

bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>)
bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025
bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025.
"Ayrmid's proposal remains highly conditional, despite an extension to the previously agreed-upon timeline to complete confirmatory diligence and submit a binding offer," said Mark Vachon, chairman of the bluebird bio Board of Directors. "bluebird has engaged with Ayrmid on two separate occasions—neither of which has resulted in a binding or fully-financed offer. After careful consideration with our financial and legal advisors, discussions with Hercules Capital, and taking into account that absent a significant infusion of capital, bluebird continues to be at significant risk of defaulting on its loan covenants, the Board unanimously reaffirms its support of the previously announced agreement with Carlyle and SK Capital in the strongest possible terms."

Penny Stocks

bluebird bio Announces That After Three Weeks Of Engagement, Ayrmid Has Not Submitted A Binding Proposal To Acquire Bluebird And Has Not Obtained Necessary Financing

Carlyle, SK Capital Partners, And Beacon Parent Holdings Announced That Beacon Merger Sub, Inc. Has Extended The Expiration Date Of Its Offer To Acquire All Of The Outstanding Common Stock Of Bluebird Bio, To Expire At One Minute After 11:59 P.M., New York City Time, On May 2, 2025

These past three months were not what U.S. <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">dealmakers wanted or expected</a>.
As of April 3, transaction tracker Dealogic showed zero percent growth in U.S.-based M&amp;A volume compared to last year&#8217;s first quarter.
Elsewhere? Volume is spiking triple digits.
<ul>
<li>The Middle East and Africa combined are seeing 123% growth in M&amp;A.</li>
<li>Japan: 105%</li>
<li>Asia: 103%</li>
</ul>
Deal volume is also up in Canada, Europe and Australia. Only in Latin America is it in the red, with <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/03/44342234/deal-dispatch-trump-ma-boom-is-a-bust-purple-mattress-considers-sale-celtics-auction-heats-up">barely a peep</a> coming from the U.S.
For those keeping track of who correctly predicted this downtrend, don&#8217;t look to Bank of America. After Election Day, the firm&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">analysts boldly predicted</a> that the then-incoming Trump administration would remove Federal Trade Commission chair Lina Khan and, presto, the antitrust roadblocks for M&amp;A activity would be removed.
Those analysts were wrong. Just 10 days after Trump&#8217;s inauguration, the U.S. Department of Justice <a href="https://www.benzinga.com/news/legal/25/01/43353124/hewlett-packard-enterprise-shares-fall-as-us-department-of-justice-sues-to-block-juniper-acquisition">sued to block</a> Hewlett Packard Enterprise&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) $14 billion deal to acquire networking gear maker Juniper Networks. In March, Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) <a href="https://julian-34159.medium.com/m-a-malaise-whats-behind-the-2025-deal-slowdown-8471a15b914c">saw its stock price fall</a> after the FTC challenged a proposed acquisition by private equity firm GTCR LLC.
Those BofA analysts also forgot that the previous Trump administration was not particularly lenient regarding consolidation. AT&amp;T and Time Warner; Sinclair and Tribune Media; Broadcom and Qualcomm; DraftKings and FanDuel — <a href="https://www.benzinga.com/news/asset-sales/25/03/44202239/deal-dispatch-tiktok-walgreens-raizen">all blocked</a>.
On the shiny side, gold-related M&amp;A deals have increased, but transaction sizes are much smaller, Benzinga&#8217;s Stjepan Kalinic <a href="https://www.benzinga.com/news/legal/25/03/44490949/gold-ma-deals-are-accelerating-but-average-deals-are-smaller-research-shows">wrote this week</a>.
See Also: <a href="https://www.benzinga.com/government/regulations/25/04/44648681/powell-cites-tariff-driven-inflation-risks-shrugs-off-trumps-call-for-perfect-time-to-cut-rates">Trump Urges Immediate Rate Cuts, Powell Says It&#8217;s &#8216;Too Soon&#8217; As Tariffs Will Likely Drive Inflation</a>
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>I Squared Capital is considering selling its European trailer-leasing business, TIP Group, which could be valued at over €3 billion ($3.2 billion). The Miami-based firm is consulting advisers but has not yet launched a formal sale process, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-02/i-squared-said-to-weigh-3-billion-sale-of-trailer-leasing-firm?srnd=phx-deals&amp;sref=TBDibEcD">reports</a>. Based in Amsterdam, TIP Group may attract interest from infrastructure funds and industry peers. I Squared acquired the company in 2018 from HNA Group and has since expanded it through acquisitions, including Trailer Wizards in Canada and Eurotrail UK Ltd. The company was rebranded as TIP Group in 2022.</li>
</ul>
<ul>
<li>Bowmark Capital is working with Arma Partners on a potential sale of workforce management software firm Totalmobile, which could be valued at over £500 million ($649 million). A formal sale process may start later this year, according <a href="https://www.bloomberg.com/news/articles/2025-04-02/pe-firm-bowmark-said-to-weigh-500-million-sale-of-totalmobile?sref=TBDibEcD">to</a> Bloomberg. Totalmobile, which provides field service management software, could attract interest from private equity firms and industry players. Bowmark acquired the company in 2020, and deliberations on the sale are still in the early stages.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Final bids for Eni SpA&#8216;s 15% stake in Plenitude, a renewables company, are expected in the coming weeks. Apollo Global Management, Ares Management and Stonepeak are among the interested parties, according to Bloomberg—initial interest values Plenitude between €12 billion and €13 billion ($14 billion).</li>
</ul>
<ul>
<li>Ayrmid Ltd. <a href="https://www.benzinga.com/25/03/44564776?57575">offered to acquire</a> Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) for an upfront cash payment of $4.50 per share. The company topped a $3.00 per share bid from private equity firms <a href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal">Carlyle and SK Capital Partners</a>.</li>
</ul>
<ul>
<li>Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44565671/rocket-acquires-mr-cooper-just-weeks-after-buying-redfin-brings-together-the-homeownership-experience-at-scale">announced it will acquire</a> Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) in an all-stock transaction for $9.4 billion in equity value. The move comes just after Rocket's $1.75 billion acquisition of <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44237879/rocket-redfin-deal-aims-to-create-end-to-end-real-estate-solution-where-does-that-leave-zillow">online real estate broker Redfin Corp. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>).&nbsp;</li>
</ul>
<ul>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) <a href="https://www.benzinga.com/25/04/44643347/hershey-expands-snack-empire-with-acquisition-of-lesserevil-for-750m">agreed to acquire</a> snack brand LesserEvil. This move reflects the confectionery giant&#8217;s ongoing effort to expand from sweets such as Reese&#8217;s and Jolly Ranchers into the better-for-you snack sector. The acquisition is <a href="https://www.wsj.com/business/deals/hershey-nears-750-million-deal-for-lesserevil-popcorn-brand-4ca3d468?mod=lead_feature_below_a_pos1" target="_blank" rel="noreferrer noopener">reportedly</a> valued at around $750 million.</li>
</ul>
<ul>
<li>Rogers Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) said on Friday it agreed to receive a 7 billion Canadian dollar (~$5 billion) equity investment from funds managed by Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), supported by <a href="https://www.benzinga.com/news/asset-sales/25/04/44646240/rogers-scores-5-billion-blackstone-deal-to-cut-debt-unlock-wireless-infrastructure-value">several Canadian institutional investors</a>.</li>
</ul>
<ul>
<li>President Trump confirmed that the U.S. is <a href="https://in.benzinga.com/general/social-media/25/02/43511395/trump-pushes-for-tiktok-deal-china-could-oblige-if-it-werent-for-those-tariffs-heres-what-we-know" target="_blank" rel="noreferrer noopener">nearing a deal</a> to spare TikTok from a potential ban, with ongoing discussions involving multiple investors and a possible tariff agreement with China. During <a href="https://www.benzinga.com/25/04/44641024/trump-says-us-close-to-tiktok-deal-reiterates-his-offer-of-tariff-relief-to-secure-chinas-consent-the-tariffs-give-us-great-power-to-negotiate">remarks aboard</a> Air Force One, Trump didn&#8217;t specify whether the &#8220;very good group of people&#8221; interested in TikTok includes OnlyFans founder Tim Stokely. AppLovin and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44645102/applovin-wants-tiktok-but-can-it-beat-amazon-and-onlyfans-to-the-punch">also reportedly interested</a>.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Hooters, the restaurant chain known for its all-female waitstaff and neon orange branding, <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">officially filed for bankruptcy protection</a>. The Chapter 11 filing allows the chain to continue normal operations during the proceeding. Hooters said that all of its 100 restaurants will be sold to two existing franchisees, which own and operate more than 30% of Hooters&#8217; locations in the U.S.</li>
</ul>
For the previous edition of <a href="https://www.benzinga.com/news/25/03/44546940/deal-dispatch-bezos-backed-crop-company-wilts-tech-startup-nabs-napster-for-207-million">Deal Dispatch, click here</a>.

Politics

AMZN

COOP

RDFN

SHEL

SRDX

Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking

Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher Monday after the company received an unsolicited takeover <a href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps">offer from Ayrmid Ltd</a>.
What To Know: The offer includes an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of net sales milestones.
The bid comes after Bluebird had already agreed in February to be acquired and taken private by Carlyle and SK Capital Partners for $3 per share in cash, with the same $6.84 contingent value right. 
Bluebird said it previously reviewed strategic alternatives and even engaged in discussions with Ayrmid, but Ayrmid did not submit a proposal at that time. The company's board is now reviewing the new offer with legal and financial advisors. Investors appear to be reacting to the possibility of a higher takeover price.
Bluebird Bio shares are also getting a boost from Barclays on Monday after the analyst firm maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and set a price target of $8.
Blue Price Action: BlueBird Bio shares were up 24.1% at $5.06 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png" alt="" class="wp-image-849883" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57.png 1494w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/03/44567966/stocks-fall-sp-500-eyes-worst-month-in-almost-two-years-oil-rallies-whats-driving-markets-monday">Stocks Fall, S&amp;P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

BlueBird Shares Are Up Today: What's Going On?

BlueBird Bio shares are trading higher after the company received a non-binding written takeover proposal from Ayrmid. Also, Barclays maintained its Overweight rating on the stock.

<h3>Gainers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock moved upwards by 88.8% to $103.12 during Monday's regular session. The market value of their outstanding shares is at $10.8 billion. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 38.2% to $35.48. The company's market cap stands at $461.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 34.34% to $0.89. The market value of their outstanding shares is at $63.9 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares rose 26.41% to $5.16. The market value of their outstanding shares is at $50.2 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares moved upwards by 13.95% to $0.57. The company's market cap stands at $8.3 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock rose 13.34% to $0.97. The market value of their outstanding shares is at $23.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares declined by 46.9% to $36.92 during Monday's regular session. The company's market cap stands at $4.7 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 34.87% to $0.99. The market value of their outstanding shares is at $11.3 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 30.87% to $0.65. The company's market cap stands at $3.4 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares fell 30.06% to $1.35. The market value of their outstanding shares is at $276.7 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 27.49% to $0.35. The market value of their outstanding shares is at $1.5 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares decreased by 23.08% to $11.17. The market value of their outstanding shares is at $166.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

CORT

CTOR

NGNE

NIVF

PCVX

TSHA

12 Health Care Stocks Moving In Monday's Intraday Session

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Ayrmid has proposed to acquire Bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achieving a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44545777/bluebird-bio-confirms-receipt-of-an-unsolicited-non-binding-proposal-from-ayrmid" rel="noreferrer noopener">net sales milestone</a>.
In February 2025, Bluebird entered into a definitive agreement with Carlyle and SK Capital Partners to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a <a target="_blank" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal" rel="noreferrer noopener">net sales milestone</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a>
Bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives.
Ayrmid did not submit any proposal to Bluebird during that process.
Consistent with its fiduciary duties, the Bluebird Board of Directors is reviewing the Ayrmid Proposal in consultation with its legal and financial advisors.
In November 2024, the FDA raised concerns about life-threatening hematologic malignancies in patients treated with Bluebird Bio&#8217;s Skysona (elivaldogene autotemcel), a gene therapy for early, active cerebral <a href="https://www.benzinga.com/general/biotech/24/11/42243241/fda-probes-potential-life-threatening-blood-cancer-risks-linked-to-bluebird-bios-skysona-gene-therapy" target="_blank" rel="noreferrer noopener">adrenoleukodystrophy (CALD)</a>.
The agency has received reports of myelodysplastic syndrome and acute myeloid leukemia linked to Skysona, with cases emerging 14 to 92 months post-treatment during clinical trials.
Price Action: BLUE stock is up 7.84% at $4.40 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544574/eye-care-topcon-goes-private-via-management-buyout-deal-of-around-22-per-share" target="_blank" rel="noreferrer noopener">Eye Care Company Topcon Goes Private Via Management Buyout Deal At Huge Premium</a></li>
</ul>
Image: Shutterstock

Trading Ideas

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Overweight and lowers the price target from $40 to $8.

Price Target

Analyst Ratings

Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $8

QSG: 50% &#x7C; <a href="https://www.benzinga.com//node/44453294">QuantaSing Group Expands Into Pop Toys Market with Strategic Acquisition Of Letsvan, Tapping High-Growth Consumer Goods Segment</a>
&nbsp;
BLUE: 30% &#x7C; <a href="https://www.benzinga.com//node/44545983">Bluebird Bio shares are trading higher after the company confirmed it received an unsolicited non-binding proposal from Ayrmid.</a>

Market-Moving News for March 31st

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 11.9% to $0.75 during Friday's after-market session. The company's market cap stands at $108.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 10.96% to $0.81. The market value of their outstanding shares is at $2.2 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 10.0% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock increased by 9.8% to $4.48. The company's market cap stands at $43.6 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares increased by 9.75% to $4.5. The market value of their outstanding shares is at $165.9 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares rose 8.89% to $0.56. The market value of their outstanding shares is at $48.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 20.5% to $0.02 during Friday's after-market session. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 16.83% to $0.17. The market value of their outstanding shares is at $2.2 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock decreased by 14.57% to $0.52. The market value of their outstanding shares is at $13.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares decreased by 14.26% to $0.37. The market value of their outstanding shares is at $19.3 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock decreased by 13.39% to $3.3. The company's market cap stands at $2.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 11.95% to $0.06. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GCTK

GELS

IPSC

LGMK

MOLN

OCEA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Friday's After-Market Session

Bluebird Bio shares are trading higher after the company confirmed it received an unsolicited non-binding proposal from Ayrmid.

bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.
As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the "Merger Agreement") with funds managed by global investment firms Carlyle and SK Capital Partners, LP to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone, contingent upon certain offer conditions (the "Merger"). bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives. Ayrmid did not submit any proposal to bluebird as part of that process. The Ayrmid Proposal is subject to certain conditions and further negotiations between the parties, including confirmatory diligence.

bluebird bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid To Acquire Bluebird For An Upfront Cash Payment Of $4.50 Per Share And A One-Time Contingent Value Right Of $6.84 Per Share Payable Upon Achievement Of A Net Sales Milestone

<a href="https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/" title="https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/">https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/</a>

'Bluebird Gets New M&A Bid, Seeking To Top Private Equity Offer' - Endpoints News

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Comments

bluebird bio

空売り

bluebird bio (NASDAQ:BLUE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル